Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | SVP Clinical Development | July 01, 2020 | July 02, 2020 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Medical Officer | March 01, 2022 | March 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date July 01, 2020 · Filed July 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,714 |
Reported balance
After 2020-07-01 transaction · row 1
1 source rowRow 1 · 2020-07-01 · Sale · Disposed 1,071 · Balance 65,714 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.
X4 Pharmaceuticals, Inc
Report date March 01, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,107 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 97,000 · Balance 104,107 F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2: Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
F2: Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 1, 2022 21:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 97,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-004495 · wf-form4_164616890458685.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,107 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:19 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-002505 · wf-form4_164487355715189.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,107 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.53 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 20:56 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 8,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-005661 · wf-form4_161670575865534.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,035 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Represents unvested restricted stock units. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 13:23 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 121,500 | $6.43 Strike: $6.43 | $781,245.00 |
DisclosureSEC source: 0001628280-21-000147 · wf-form4_160993939587870.xml · derivative · entry 1 Cadavid Diego · CIK 0001778713 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,500 Underlying: Common Stock · 121,500 shares Expires 2030-12-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on December 31, 2021, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:19 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 1,071 | $18.30 | $19,599.30 |
DisclosureSEC source: 0000899243-20-018278 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,714 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 1,459 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-017761 · doc4.xml · derivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,277 Underlying: Common Stock · 1,459 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 1,459 | $22.00 | $32,098.00 |
DisclosureSEC source: 0000899243-20-017761 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 1,459 | $4.83 | $7,046.97 |
DisclosureSEC source: 0000899243-20-017761 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 401 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-016382 · doc4.xml · derivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,736 Underlying: Common Stock · 401 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 401 | $22.00 | $8,822.00 |
DisclosureSEC source: 0000899243-20-016382 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 401 | $4.83 | $1,936.83 |
DisclosureSEC source: 0000899243-20-016382 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 451 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · derivative · entry 6 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,137 Underlying: Common Stock · 451 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F4 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 451 | $20.18 | $9,100.77 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 4 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 451 | $4.83 | $2,178.33 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 226 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · derivative · entry 5 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,588 Underlying: Common Stock · 226 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F4 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 226 | $20.05 | $4,531.25 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:17 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 226 | $4.83 | $1,091.58 |
DisclosureSEC source: 0000899243-20-015623 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 338 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · derivative · entry 6 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,814 Underlying: Common Stock · 338 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 338 | $20.18 | $6,819.59 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 4 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.41, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 338 | $4.83 | $1,632.54 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 45 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · derivative · entry 5 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,152 Underlying: Common Stock · 45 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 45 | $20.00 | $900.00 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 45 | $4.83 | $217.35 |
DisclosureSEC source: 0000899243-20-015245 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 200 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · derivative · entry 6 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,197 Underlying: Common Stock · 200 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 200 | $20.04 | $4,007.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 4 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.07, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 200 | $4.83 | $966.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · derivative · entry 5 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,397 Underlying: Common Stock · 600 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 600 | $20.00 | $12,000.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 600 | $4.83 | $2,898.00 |
DisclosureSEC source: 0000899243-20-014722 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 12, 2020 Filed May 12, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock Option (right to buy) · Derivative | 1,860 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-20-012822 · doc4.xml · derivative · entry 3 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,997 Underlying: Common Stock · 1,860 shares Expires 2028-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022. Read SEC document |
| May 12, 2020 Filed May 12, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 1,860 | $18.00 | $33,480.00 |
DisclosureSEC source: 0000899243-20-012822 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| May 12, 2020 Filed May 12, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 1,860 | $4.83 | $8,983.80 |
DisclosureSEC source: 0000899243-20-012822 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 23:42 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 315 | $18.13 | $5,709.53 |
DisclosureSEC source: 0000899243-20-006590 · doc4.xml · nonDerivative · entry 2 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,785 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 23:42 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 1,828 | $17.26 | $31,545.25 |
DisclosureSEC source: 0000899243-20-006590 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.91 to $17.85, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:31 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 2,143 | $17.33 | $37,141.83 |
DisclosureSEC source: 0000899243-20-003272 · doc4.xml · nonDerivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,928 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.06 to $17.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 55,440 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0000899243-20-002040 · doc4.xml · derivative · entry 1 Cadavid Diego · CIK 0001778713 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,440 Underlying: Common Stock · 55,440 shares Expires 2030-01-22 F1 · derivative.exercise_date: This option was granted on January 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2020, subject to continued service. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 21:26 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 12,784 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-19-040967 · a4.xml · derivative · entry 1 Cadavid Diego · CIK 0001778713 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,784 Underlying: Common Stock · 12,784 shares Expires 2029-07-17 F1 · derivative.exercise_date: The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments from July 1, 2019 through June 30, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.